Related Substances Testing for Traditional Chinese Medicine Injections: Analytical Strategies, Metho

Related substances testing is a critical quality control requirement for Traditional Chinese Medicine (TCM) injections, ensuring that degradation products, process-related impurities, and extractable contaminants remain within safe limits for parenteral administration. This article provides a comprehensive technical overview of related substances testing for TCM injections, covering sample types, testing items, analytical methods such as HPLC and LC-MS, regulatory requirements, and practical applications in pharmaceutical quality assurance.

Technical Overview

Traditional Chinese Medicine injections (TCMIs) are sterile parenteral preparations manufactured from herbal extracts, and they are administered directly into the bloodstream through intravenous, intramuscular, or subcutaneous routes. Because these products bypass the natural defense barriers of the human body, such as the gastrointestinal tract and the hepatic first-pass effect, any impurity present in the formulation has the potential to trigger serious adverse reactions, including anaphylaxis, pyrogenic responses, and organ toxicity. For this reason, related substances testing represents one of the most stringent and essential elements of the quality control system for TCM injections.

Related substances, often referred to as related compounds or impurities, encompass any components present in the finished product that are not the intended active constituents or excipients. In the context of TCM injections, these impurities may originate from multiple sources, including the inherent chemical complexity of the herbal raw materials, degradation of active markers during extraction and sterilization, residual proteins, tannins, and resins from incomplete purification, as well as degradation products formed during storage. Regulatory authorities, including the National Medical Products Administration (NMPA) of China and international agencies, mandate comprehensive impurity profiling as a condition for product registration and commercial batch release. The Chinese Pharmacopoeia (ChP) general requirements, together with ICH Q3A and Q3B guidelines, form the primary regulatory framework governing acceptable impurity levels and analytical expectations.

Testing Samples

Finished Injection Products

Commercial and registration batches of TCM injections supplied in ampoules, vials, or pre-filled syringes constitute the primary testing samples. These products are analyzed in their final packaged form to verify that impurity levels comply with registered specifications. Testing covers multiple wavelengths and chromatographic conditions to capture the full impurity profile of the complex matrix.

Bulk Solutions and Manufacturing Intermediates

In-process control samples, including water extraction concentrates, alcohol precipitation fractions, and purified bulk solutions, are tested to identify at which manufacturing stage impurities are introduced or removed. This information supports process optimization and helps manufacturers establish in-process impurity control limits.

Herbal Raw Materials and Reference Extracts

Crude herbal materials, processed slices, and reference extract lots are analyzed to establish the baseline impurity profile of the starting materials. Because herbal origin, harvest season, and post-harvest handling significantly influence impurity levels, raw material characterization is essential for differentiating process-derived impurities from naturally occurring related compounds.

Stability Study Samples

Samples stored under accelerated conditions (typically 40°C and 75% relative humidity) and long-term conditions (25°C and 60% relative humidity) are periodically tested to monitor impurity growth over the proposed shelf life. Photostability and stress-conditioned samples are also included to evaluate degradation pathways and support analytical method suitability.

Testing Items

Related substances testing for TCM injections involves a structured set of analytical evaluations designed to quantify and characterize the full impurity landscape:

• Total impurity content: the sum of all detectable impurity peaks expressed as a percentage relative to the main active marker constituents.
• Individual specified impurities: quantification of known impurities with established structural identity and defined acceptance limits, such as degradation products of key active markers.
• Unspecified impurities: any unknown impurity peaks exceeding the reporting threshold, typically controlled at or below 0.10 percent relative to the main peak.
• Macromolecular impurities: residual proteins, peptides, polysaccharides, and nucleic acids that may provoke immunogenic or anaphylactoid reactions.
• Tannin and resin residues: incompletely removed polyphenols and resinous matter that contribute to injection-site irritation and instability.
• Oxidation and hydrolysis products: degradation compounds formed through exposure to oxygen, light, elevated temperature, or pH shifts during processing and storage.
• Residual solvents and process chemicals: traces of ethanol, acetone, or extraction and purification reagents remaining from manufacturing.
• Interaction products: impurities arising from container-closure interactions, such as leachables and extractables from glass ampoules or rubber stoppers.

Testing Methods

A tiered analytical strategy is applied to separate, quantify, and identify related substances in TCM injections, combining orthogonal chromatographic techniques with advanced structural elucidation tools.

High Performance Liquid Chromatography (HPLC-DAD)

HPLC coupled with diode array detection is the workhorse method for related substances analysis. Gradient reversed-phase separations using C18 columns allow resolution of impurity profiles, while diode array detection enables spectral purity assessment and multi-wavelength monitoring. Quantification is commonly performed by either the external standard method against reference substances or the self-comparison method normalized to the main peak area, in accordance with the monograph requirements of the Chinese Pharmacopoeia.

Ultrahigh Performance Liquid Chromatography (UHPLC)

UHPLC methods employing sub-2-micron particles deliver superior resolution, shorter run times, and improved sensitivity, which is particularly valuable for resolving the dense impurity profiles characteristic of multi-component herbal matrices. UHPLC is increasingly adopted for routine release testing and stability monitoring.

Liquid Chromatography-Mass Spectrometry (LC-MS and LC-MS/MS)

When unknown impurities exceed identification thresholds, LC-MS/MS analysis provides accurate mass measurement and fragmentation data to support structural elucidation. High-resolution mass spectrometry enables discrimination of isobaric impurities and supports toxicological risk assessment of newly detected degradation products.

Gas Chromatography (GC and GC-MS)

GC with flame ionization or mass spectrometric detection is applied for volatile impurities, including residual solvents and certain thermally stable degradation compounds, following headspace sampling procedures aligned with ChP residual solvent requirements.

Supplementary Techniques

• Size exclusion chromatography (SEC) for the detection of macromolecular impurities and aggregates.
• Thin layer chromatography (TLC) for rapid screening of tannins, resins, and specific marker impurities in accordance with classical monograph methods.
• Capillary electrophoresis as an orthogonal separation technique for ionic and highly polar impurities.
• Forced degradation studies under acid, base, oxidative, thermal, and photolytic stress conditions to demonstrate method specificity and stability-indicating capability.

Method Validation

All analytical methods must be validated in accordance with ICH Q2(R2) and ChP guidelines, demonstrating specificity, linearity, accuracy, precision, detection limit, quantitation limit, range, and robustness. Stability-indicating capability must be confirmed by demonstrating that impurity peaks are chromatographically resolved from the active constituents and excipient peaks under all relevant degradation conditions.

Applications

Related substances testing for TCM injections serves a wide range of practical and regulatory purposes across the product lifecycle:

• Commercial batch release testing to confirm compliance with registered impurity specifications before distribution.
• New drug registration and post-approval change submissions, where comprehensive impurity profiling data support safety evaluation by regulatory authorities.
• Stability studies for shelf-life determination and storage condition justification.
• Manufacturing process development and optimization, including evaluation of extraction, purification, and sterilization steps for impurity reduction.
• Investigation of adverse drug reactions and product quality complaints, where impurity fingerprinting helps identify root causes.
• Consistency evaluation of generic TCM injections, demonstrating impurity profiles comparable to the reference listed product.
• Container-closure and packaging compatibility studies assessing leachables and extractables.
• Supplier qualification of herbal raw materials through baseline impurity profiling.

FAQ

What are related substances in TCM injections?

Related substances are chemical entities present in a TCM injection other than the intended active constituents and excipients, including degradation products, residual macromolecules such as proteins and tannins, extraction process residues, and impurities formed during storage. Because injections enter the systemic circulation directly, these substances must be tightly controlled to prevent adverse reactions.

Why is related substances testing more critical for injections than for oral TCM products?

Oral dosage forms benefit from gastrointestinal barriers and hepatic metabolism that attenuate the impact of many impurities, whereas intravenously administered TCM products contact blood and tissues directly without such protection. Consequently, impurities that would be tolerable in oral forms may cause hemolysis, anaphylaxis, or pyrogenic reactions in injectable products, justifying far stricter impurity limits.

Which regulatory standards govern related substances testing for TCM injections?

The Chinese Pharmacopoeia provides monograph-specific impurity requirements and general chapters on chromatographic methods and method validation. ICH Q3A and Q3B guidelines define impurity classification, thresholds, and identification requirements, while NMPA technical guidance documents for TCM injections specify additional safety-oriented controls such as macromolecule and pyrogen testing.

How are unknown impurities handled when they exceed the identification threshold?

When an unknown impurity exceeds established identification thresholds, typically ranging from 0.10 to 0.20 percent depending on daily dose, LC-MS/MS structural elucidation is performed to determine its molecular identity. The impurity is then evaluated for toxicological risk, assigned a specification limit, and either added to the routine monitoring panel or eliminated through process improvement.

What is the self-comparison method in impurity quantification?

The self-comparison method quantifies impurity peak areas as a percentage of the diluted main peak area, eliminating the need for isolated impurity reference standards. This approach, widely used in Chinese Pharmacopoeia monographs, is appropriate when impurity response factors are assumed similar to that of the main component, and it is often cross-verified with external standard quantification for critical impurities.

How long does related substances testing typically take?

Standard release testing against an established method generally requires several working days, including sample preparation, duplicate chromatographic runs, and data review. Full method development and validation projects, including forced degradation studies and impurity identification, typically require several weeks to several months depending on matrix complexity and the number of impurities requiring structural elucidation.